A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
Paul Rutgeerts(KU Leuven), Sharon O’Byrne, Daan W. Hommes(Leiden University Medical Center), John Mansfield(Newcastle University), Daniel C. Baumgart(University of Alberta), Meina Tang, Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Mary Keir(California Institute for Regenerative Medicine), Andreas Sturm(German Red Cross), Jackson G. Egen(Amgen (United States)), Jennifer Visich, Xiaohui Wei, Marna Williams(Stanford University), Diana Luca(Ultragenyx Pharmaceutical (United States)), Brian Bressler(University of British Columbia), Richard N. Fedorak(University of Alberta)
Cited by 151
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k